No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients
Background : Hypercoagulability is an important risk factor for thrombosis and its complications in hemodialysis patients . This study was design ed to investigate the effects of l-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients . Methods : Thirty-six hemodialysis patients were r and omly assigned to either a carnitine or a placebo group . Patients in the carnitine group received 1000 mg/day oral l-carnitine for 12 weeks , whereas patients in the placebo group received a corresponding placebo . At baseline and the end of week 12 , 5 mL blood was collected after a 12- to 14-hour fast and plasma fibrinogen concentration , activity of plasma protein C , coagulation factors V , VII , IX , and serum concentrations of tissue plasminogen activator ( tPA ) , plasminogen activator inhibitor type-1 ( PAI-1 ) , free carnitine , and C-reactive protein ( CRP ) were measured . Results : In the carnitine group , mean serum free carnitine concentration increased significantly to 150 % of baseline ( p < 0.001 ) , whereas plasma fibrinogen and serum CRP had 98 mg/dL ( p < 0.01 ) and 41 % ( p < 0.01 ) significant decreases , respectively , at the end of week 12 compared with baseline . The reductions were significant compared with the placebo group ( p < 0.05 ) . No significant differences were observed between the two groups with regard to mean changes of the activity of plasma protein C , coagulation factors V , VII , IX , and serum PAI-1 to tPA ratio . Conclusion : l-Carnitine supplement reduces serum CRP , a marker of systemic inflammation , and plasma fibrinogen , an inflammation-related coagulation factor , in hemodialysis patients . Therefore , l-carnitine may play an effective role in preventing cardiovascular diseases in these patients
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .